Oxyquinoline
CAS 148-24-3
Oxyquinoline (CAS 148-24-3) is a pharmaceutical compound with 6 bioactivity targets and 30 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 20213.49507936508 nM | 70 | - |
| - | Potency | 18956.910344827586 nM | 68 | - |
| - | IC50 | 26073.282258064515 nM | 59 | - |
| - | AC50 | 28040.148387096775 nM | 31 | - |
| - | IC50 | 16.563333333333333 ug.mL-1 | 9 | - |
| - | MIC | 28907.5 nM | 4 | - |
| - | MIC | 15.653749999999999 ug.mL-1 | 4 | - |
| - | EC50 | 14497 nM | 2 | - |
| - | Ki | 370 nM | 2 | - |
| 72 kDa type IV collagenase Enzyme |
IC50 | 3.89 | - | Homo sapiens |
| Catechol O-methyltransferase Enzyme |
IC50 | 5.8 | - | Homo sapiens |
| Histone deacetylase 8 Enzyme |
EC50 | 4.96 | - | Homo sapiens |
| Methionine aminopeptidase 2 Enzyme |
IC50 | 5.69 | - | Homo sapiens |
| Catechol O-methyltransferase Enzyme |
IC50 | 4.67 | - | Rattus norvegicus |
| Methionine aminopeptidase 1 Enzyme |
IC50 | 4.67 | - | Homo sapiens |
| Bacterial leucyl aminopeptidase Enzyme |
Ki | 6.8 | - | Vibrio proteolyticus |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Apparent death | 47 | 243.83 | 10067476 |
| Intestinal sepsis | 24 | 146.048 | 10075622 |
| Diverticulitis | 48 | 133.469 | 10013538 |
| Pulmonary thrombosis | 33 | 122.402 | 10037437 |
| Terminal state | 26 | 113.75 | 10048669 |
| Photosensitivity reaction | 32 | 102.645 | 10034972 |
| C-reactive protein increased | 52 | 101.865 | 10006825 |
| Pulmonary embolism | 57 | 101.408 | 10037377 |
| Deep vein thrombosis | 49 | 95.362 | 10051055 |
| Red blood cell sedimentation rate increased | 34 | 84.939 | 10049187 |
| Joint arthroplasty | 18 | 81.971 | 10057681 |
| C-reactive protein abnormal | 32 | 77.948 | 10068559 |
| Renal failure | 48 | 68.657 | 10038435 |
| Allergy to plants | 12 | 66.401 | 10054928 |
| Thrombosis | 34 | 62.235 | 10043607 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| OXYQUINOLINE | 110 | SU | MTHSPL |
| oxyquinoline | 110 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Oxyquinoline used for in pharmaceutical contexts?
Oxyquinoline (CAS 148-24-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Oxyquinoline?
Oxyquinoline has 30 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Apparent death, Intestinal sepsis, Diverticulitis, Pulmonary thrombosis, Terminal state. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Oxyquinoline also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for OXYQUINOLINE with EU status "restricted".
What clinical phase is Oxyquinoline in?
No phase 1-4 clinical development badge is rendered for Oxyquinoline because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Oxyquinoline?
Oxyquinoline has 16 bioactivity rows in this page query. Rendered target entries include 72 kDa type IV collagenase, Catechol O-methyltransferase, Histone deacetylase 8, Methionine aminopeptidase 2, Methionine aminopeptidase 1.